Equities Analysts Issue Forecasts for VTVT Q1 Earnings

vTv Therapeutics Inc. (NASDAQ:VTVT) – Research analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of vTv Therapeutics in a research note issued to investors on Wednesday, April 9th. HC Wainwright analyst E. Bodnar anticipates that the biotechnology company will post earnings per share of ($0.73) for the quarter. HC Wainwright has a “Buy” rating and a $36.00 price objective on the stock. HC Wainwright also issued estimates for vTv Therapeutics’ Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($1.08) EPS, Q4 2025 earnings at ($1.24) EPS, FY2025 earnings at ($3.97) EPS, FY2026 earnings at ($3.57) EPS, FY2027 earnings at ($3.94) EPS, FY2028 earnings at ($3.67) EPS and FY2029 earnings at ($2.70) EPS.

vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings results on Thursday, March 20th. The biotechnology company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($0.87) by $0.32. The firm had revenue of $0.02 million for the quarter.

Separately, StockNews.com started coverage on vTv Therapeutics in a research report on Thursday, March 27th. They set a “sell” rating on the stock.

vTv Therapeutics Trading Up 3.8 %

vTv Therapeutics stock opened at $18.77 on Thursday. vTv Therapeutics has a 12 month low of $12.12 and a 12 month high of $29.19. The stock has a fifty day simple moving average of $17.93 and a two-hundred day simple moving average of $15.76. The firm has a market cap of $59.88 million, a price-to-earnings ratio of -4.14 and a beta of 0.81.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. bought a new stake in vTv Therapeutics in the 4th quarter worth approximately $25,000. Geode Capital Management LLC boosted its stake in shares of vTv Therapeutics by 12.9% in the 4th quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock worth $158,000 after buying an additional 1,327 shares during the last quarter. Finally, FMR LLC bought a new stake in shares of vTv Therapeutics in the third quarter worth $2,402,000. 17.51% of the stock is owned by hedge funds and other institutional investors.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.